WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1999040881) SPECIFIC ANTIBODIES AGAINST MAMMARY TUMOR-ASSOCIATED MUCIN, METHOD FOR PRODUCTION AND USE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1999/040881    International Application No.:    PCT/EP1999/000941
Publication Date: 19.08.1999 International Filing Date: 12.02.1999
Chapter 2 Demand Filed:    08.09.1999    
IPC:
A61K 38/00 (2006.01), C07K 16/18 (2006.01), C07K 16/30 (2006.01)
Applicants: BASTERT, Gunther [DE/DE]; (DE).
KAUL, Sepp [DE/DE]; (DE) (For US Only)
Inventors: BASTERT, Gunther; (DE).
KAUL, Sepp; (DE)
Agent: PÄTZOLD, Herbert; Steubstrasse 10, D-82166 Gräfelfing (DE)
Priority Data:
98102529.9 13.02.1998 EP
Title (EN) SPECIFIC ANTIBODIES AGAINST MAMMARY TUMOR-ASSOCIATED MUCIN, METHOD FOR PRODUCTION AND USE
(FR) ANTICORPS SPECIFIQUES DE LA MUCINE ASSOCIEE AU CANCER DU SEIN, ET TECHNIQUE DE PRODUCTION ET UTILISATION ASSOCIEES
Abstract: front page image
(DE)An immunologically actie polypeptide which specifically binds to the carbohydrate structure of the MUC1 tandem repeat from carcinoma cells, wherein a) the quotient between the affinity of the said polypeptide for a (200 to 400 kDa) glycoprotein fraction from tumor cell-containing ascites of breast cancer patients and or native MUC1 antigen (400 to 440 kDa) from normal cell is 100 : 1 or more, b) the polypeptide does not bind to nonglycosylated MUC1 antigen, and c) the binding of the polypeptide to the said (200 to 440 kDa) glycoprotein fraction changes by 10% or less if the glycoprotein fraction was treated with neuraminidase to cleave N-terminal neuraminic acids, or with formalin, is specific for MUC1 and is useful in the diagnosis and therapy of breast cancer.
(EN)An immunologically active polypeptide which specifically binds to the carbohydrate structure of the MUC1 tandem repeat from carcinoma cells, wherein a) the quotient between the affinity of the said polypeptide for a 200 to 440 kDa glycoprotein fraction from tumor cell-containing ascites of breast cancer patients and for native MUC1 antigen (400 to 440 kDa) from normal cells is 100:1 or more, b) the polypeptide does not bind to nonglycosylated MUC1 antigen, and c) the binding of the polypeptide to the said 200 to 440 kDa glycoprotein fraction changes by 10 % or less if the glycoprotein fraction was treated with neuraminidase to cleave N-terminal neuraminic acids, or with formalin. The immunologically active polypeptide, e.g. antibody, is useful in the diagnosis and therapy of breast cancer.
(FR)Polypeptide à activité immunologique, qui se lie spécifiquement à la structure glucidique des séquences MUC1 répétées en tandem provenant de cellules carcinomateuses, pour lequel: a) le quotient de l'affinité du polypeptide d'une part pour une fraction glycoprotéique de 200 à 440 kDa provenant du liquide d'ascite riche en cellules de patientes atteintes d'un cancer du sein et d'autre part pour l'antigène MUC1 natif (400 à 440 kDa) provenant de cellules normales est égal ou supérieur à 100/1; b) le polypeptide ne se lie pas à l'antigène MUC1 non glycosylé; et c) la liaison du polypeptide à la fraction glycoprotéique de 200 à 440 kDa est modifiée de 10 % ou moins si ladite fraction a été traitée par la neuraminidase, qui clive les acides neuraminiques N-terminaux, ou par la formaline. Ce polypeptide spécifique de MUC1 est utile pour le diagnostic et le traitement du cancer du sein.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)